Catalent Develops New Decorin Molecule Form, Strikes Deal With
Euclid
Released
on: October 23, 2009, 7:46 am
Author: Jennings and Co.
Industry: Pharmaceuticals
SOMERSET,
NJ -Catalent Pharma Solutions, a leading provider of advanced
technologies and outsourced development and clinical services
to the global pharmaceutical and biotechnology
industry, has announced the development of the Galacorin™
molecule, a proprietary form of the decorin molecule.
Catalent
combined its proprietary GPEx® gene expression technology,
Triplet-FixTM codon optimization technology and advanced scientific
capabilities to greatly improve production and secretion of the
GalacorinTM molecule in CHO cells. In addition, Catalent has developed
a full cGMP production process for the GalacorinTM molecule.
Catalent
has reached an agreement to provide the GalacorinTM molecule to
Euclid Systems of Herndon, Virginia for an ophthalmic clinical
trial. Financial terms of the agreement have not been disclosed.
Additionally, Catalent is in the process of seeking partners for
other indications.
Catalent’s
proprietary GPEx® method of cell line engineering generates
high-expressing, genetically stable cells for all mammalian cell
types. Antibiotic selection is not needed as part of the procedure;
multiple gene constructs can be added individually, at different
gene ratios without any requirement for antibiotic resistance
markers. The method allows re-production of cellular pathways
within mammalian cell types as well as the ability to easily add
protein processing enzymes to an already established cell line.
Using conventional gene insertion and expression techniques, developing
a stable biosimilar production cell line for a target protein
can take as long as 18 months. Catalent’s GPEx® technology
can overcome the inefficiencies of conventional systems and deliver
a stable production cell line for target proteins in as little
as 4.5 months.
For
more information on Catalent’s broad range of drug and biologic
development services, go to www.catalent.com/development.
About Catalent
Headquartered in Somerset, New Jersey, Catalent is one of the
leading providers of advanced dose form and packaging technologies,
and development, manufacturing, packaging and printing services
for pharmaceutical, biotechnology
and consumer healthcare companies in nearly 100 countries. Catalent
applies its local market expertise and technical creativity to
advance treatments, change markets and enhance patient outcomes.
Catalent employs approximately 9,500 at 30 facilities worldwide
and in fiscal 2009 generated more than $1.6 billion of annual
revenue. For more information, visit www.catalent.com.
Contact Details: Patricia A. McGee
(732) 537 6407
patricia.mcgee@catalent.com
2010
